Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
182 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015', provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Relapsing Remitting Multiple Sclerosis (RRMS) Overview 10 Therapeutics Development 11 Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview 11 Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis 12 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies 13 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes 17 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies 21 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes 24 Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development 25 AbbVie Inc. 25 Actelion Ltd 26 Allozyne, Inc. 27 Amarna Therapeutics B.V. 28 Antisense Therapeutics Limited 29 Biocon Limited 30 Biogen, Inc. 31 Cognosci, Inc. 32 F. Hoffmann-La Roche Ltd. 33 Forward Pharma A/S 34 Genmab A/S 35 GlaxoSmithKline Plc 36 Iltoo Pharma 37 Mapi Pharma Ltd. 38 MedImmune, LLC 39 Merck KGaA 40 Mitsubishi Tanabe Pharma Corporation 41 Neurotec Pharma SL 42 Novartis AG 43 Octapharma AG 44 Opexa Therapeutics, Inc. 45 RedHill Biopharma Ltd. 46 Sanofi 47 Synthetic Biologics, Inc. 48 Teva Pharmaceutical Industries Limited 49 Xenetic Biosciences plc 50 Zydus Cadila Healthcare Limited 51 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 57 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 (rifabutin + clarithromycin + clofazimine) - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 aldesleukin - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 amiselimod hydrochloride - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ATL-1102 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 AZ-17 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Cell Therapy for Relapsing Remitting Multiple Sclerosis - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 cladribine - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 COG-133 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 daclizumab - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 diazoxide - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 dimethyl fumarate - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 estriol - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 glatiramer acetate ER - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 GSK-239512 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Guanabenz - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 HR-411 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 hydralazine - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 imilecleucel-t - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 immune globulin (human) - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 inebilizumab - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 interferon beta-1b - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 interferon beta-1b - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 itolizumab - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 laquinimod sodium - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 M-2736 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 MyeloXen - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 ocrelizumab - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 ofatumumab - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 olesoxime - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 opicinumab - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 Pegylated Interferon-Beta-1b - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 ponesimod - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 siponimod - Drug Profile 127 Product Description 127 Mechanism of Action 127 R&D Progress 127 Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 129 Product Description 129 Mechanism of Action 129 R&D Progress 129 vatelizumab - Drug Profile 130 Product Description 130 Mechanism of Action 130 R&D Progress 130 Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates 131 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects 168 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products 170 Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones 171 Featured News & Press Releases 171 Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS 171 Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress 173 Jun 25, 2015: Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial 173 Jun 09, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis 174 Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting 175 Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis 176 Nov 04, 2014: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis 177 Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 177 Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting 179 Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting 180 Appendix 181 Methodology 181 Coverage 181 Secondary Research 181 Primary Research 181 Expert Panel Validation 181 Contact Us 181 Disclaimer 182
List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2015 11 Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 14 Number of Products under Development by Companies, H2 2015 (Contd..1) 15 Number of Products under Development by Companies, H2 2015 (Contd..2) 16 Number of Products under Investigation by Universities/Institutes, H2 2015 17 Comparative Analysis by Late Stage Development, H2 2015 18 Comparative Analysis by Clinical Stage Development, H2 2015 19 Comparative Analysis by Early Stage Development, H2 2015 20 Products under Development by Companies, H2 2015 21 Products under Development by Companies, H2 2015 (Contd..1) 22 Products under Development by Companies, H2 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2015 24 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H2 2015 25 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H2 2015 26 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Allozyne, Inc., H2 2015 27 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H2 2015 28 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H2 2015 29 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biocon Limited, H2 2015 30 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H2 2015 31 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H2 2015 32 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 33 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H2 2015 34 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Genmab A/S, H2 2015 35 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline Plc, H2 2015 36 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H2 2015 37 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H2 2015 38 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H2 2015 39 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H2 2015 40 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 41 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H2 2015 42 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H2 2015 43 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H2 2015 44 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H2 2015 45 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H2 2015 46 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Sanofi, H2 2015 47 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Synthetic Biologics, Inc., H2 2015 48 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 49 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Xenetic Biosciences plc, H2 2015 50 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 51 Assessment by Monotherapy Products, H2 2015 52 Assessment by Combination Products, H2 2015 53 Number of Products by Stage and Target, H2 2015 55 Number of Products by Stage and Mechanism of Action, H2 2015 58 Number of Products by Stage and Route of Administration, H2 2015 61 Number of Products by Stage and Molecule Type, H2 2015 63 Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H2 2015 131 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H2 2015 168 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H2 2015 169 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H2 2015 170
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
